Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
- PMID: 32278362
- PMCID: PMC7158940
- DOI: 10.1016/S0140-6736(20)30858-8
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Comment in
-
Prevention of the cytokine storm in COVID-19.Lancet Infect Dis. 2021 Jan;21(1):25-26. doi: 10.1016/S1473-3099(20)30376-5. Epub 2020 May 7. Lancet Infect Dis. 2021. PMID: 32386610 Free PMC article. No abstract available.
-
ACTH 1-24 and other melanocortins for COVID-19 treatment.Shock. 2020 Nov;54(5):701-702. doi: 10.1097/SHK.0000000000001604. Shock. 2020. PMID: 32590699 No abstract available.
-
High levels of TNFα in patients with COVID-19 refractory to tocilizumab.Eur J Cancer. 2021 May;149:102-104. doi: 10.1016/j.ejca.2021.01.056. Epub 2021 Mar 20. Eur J Cancer. 2021. PMID: 33848711 Free PMC article. No abstract available.
References
-
- European Centre for Disease Prevention and Control COVID-19 situation update worldwide, as of 8 April 2020. https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases
-
- Gerriets V, Bansal P, Khaddour K. Publishing; Treasure Island, FL: 2020. Tumor necrosis factor (TNF) inhibitors.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
